Prodrug of ganetespib

持续的HSP90抑制导致体外客户端蛋白的持久不稳定；然而，短暂暴露需要>10倍的药物才能产生类似的效果[1]。

在体内，KIT在单剂量HSP90i后迅速降解，但在一天内恢复到基线水平。HSP90水平在HSP90i暴露16小时后增加并稳定，在随后的近期暴露后没有升高，提供了稳定蛋白质的伴侣蛋白的功能库，并为HSP90i再暴露提供了更大的治疗活性的手段。在KIT或EGFR驱动的小鼠肿瘤模型中，与D1治疗相比，在第1天和第2天给予的HSP90i（D1/D2）显示出增加的生物活性。在一项MCT犬试验中，与D1和D1/D4方案相比，D1/D2给药HSP90i与KIT持续下调、50%的客观有效率和100%的临床获益率相关。

HSP90结合测定。[1]
H1975细胞在RPMI-1640和10%FBS中培养，以每孔3×105个细胞的密度接种在6孔板中。24小时后，按指示用ganetespib处理细胞，并在37°C下孵育。细胞在冷PBS中洗涤两次，然后在冷HSP90结合缓冲液（20mM HEPES pH 7.3、1mM EDTA、100mM KCl、5mM MgCl、0.01%v/v NP-40、0.5mg/mL牛丙种球蛋白、1mM TCEP）中裂解，在冰上孵育10分钟，然后进行三次冷冻/解冻循环。通过在14000 x g下离心来澄清裂解物。为了去除未结合的ganetespib，将裂解物通过40K MWCO尺寸的排除柱。为了滴定未被占据的HSP90结合位点，将10μM的氘化形式的甘尼特spib（D3甘尼特Spib）添加到洗脱液中，并在4°C下孵育2小时，然后通过尺寸排除柱以去除未结合的D3甘尼特斯pib。通过BCA蛋白质测定法对流经的总蛋白质进行定量，并将所有样品稀释至1 mg/mL。通过LC/MS-MS测量ganetespib和D3的浓度。使用Phenomenex Kinetex柱（C18，30×2.1 mm，2.6µm），每个样品的运行时间为3.5分钟。使用以下方程来计算与HSP90结合的ganetespib的百分比（HSP90占有率）：[ganetespib]/（[ganetespib]+[D3-ganetespip]）x100[1]。

蛋白质印迹[1]
在体外测定之后，将肿瘤细胞在冰上的裂解缓冲液中破坏10分钟。为了进行药效学分析，切除异种移植物肿瘤（平均体积为100-200 mm3），切成两半，并在液氮中快速冷冻。使用FastPrep-24匀浆器和裂解基质a将每个肿瘤片段裂解在0.5mL裂解缓冲液中。通过离心澄清裂解物，并在转移到硝化纤维素膜之前通过SDS-PAGE解析等量的蛋白质。用起始阻断T20阻断缓冲液阻断膜，并用指示的抗体进行免疫印迹。抗体-抗原复合物使用奥德赛系统（LI-COR）进行可视化。

Female CB.17 (SCID) mice at 7–12 weeks of age were maintained in a pathogen-free environment and all in vivo procedures were approved by the Synta Pharmaceuticals Corp. Institutional Animal Care and Use Committee. Human GIST882 cells were provided by Dr. Jonathan Fletcher (Dana Farber Cancer Institute) and implanted subcutaneously at 10 × 106 into mice. Mice bearing established tumors (~110 mm3) were randomized into treatment groups of 8 and dosed intravenously with vehicle or ganetespib, formulated in DRD (10% DMSO, 18% Cremophor RH 40, 3.6% dextrose), using the schedules indicated. Human H1975 NSCLC cells were purchased from the ATCC, selected to stably express a HIF-1α-LUC reporter and implanted at 10 × 106 into mice. Mice bearing established tumors (~143 mm3) were randomized into treatment groups of 4 and dosed intravenously with vehicle or ganetespib, formulated in DRD, using the schedules indicated. Tumor volumes (V) were calculated by caliper measurements of the width (W), length (L) and thickness (T) of each tumor using the formula: V=0.5236(LWT). Tumor growth inhibition was determined as described previously.[1]

Absorption, Distribution and Excretion
Bioavailability is 58-70% following oral administration, compared to parenteral forms (i.v. and i.m. = 100%).

---

Biological Half-Life
t1/2-alpha = minutes (10-20 minutes in rat); t1/2-beta = a few hours

Hepatotoxicity
Defibrotide therapy has not been linked to serum aminotransferase elevations or with instances of clinically apparent liver injury separate from the features of SOS for which it is given. In a trial of defibrotide as prophylaxis against SOS conducted in 356 children undergoing HCT, rates of severe adverse events such as hemorrhage, gastrointestinal complaints and liver injury were similar in those receiving defibrotide as in untreated children.
Likelihood score: E (unlikely cause of clinically apparent acute liver injury).

[1]. Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors. Clin Cancer Res. 2018 Dec 15;24(24):6396-6407.

Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. In the USA it is was approved in March, 2016 as Defitelio.
Defibrotide is a complex mixture of single stranded polydeoxyribonucleotides derived from porcine intestinal mucosa that has antithrombotic and profibrinolytic activity and is used in the treatment of severe sinusoidal obstruction syndrome (SOS) after hematopoietic cell transplantation (HCT). Defibrotide is used in patients with severe liver injury and has not been associated with worsening of serum aminotransferase elevations during therapy and has not been linked to cases of clinically apparent, idiosyncratic liver injury.
Defibrotide is a mixture of single-stranded oligodeoxyribonucleotides derived from the intestinal mucosa of pigs, with anti-thrombotic, thrombolytic, and fibrinolytic activities. Upon administration, and although the exact mechanism of action has yet to be fully elucidated, defibrotide induces the release of prostaglandin I2 (PGI2), E2 (PGE2), and prostacyclin and reduces the expression of adhesion molecules on endothelial cells. This relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other and to the endothelium. This protects the endothelium lining bloods vessels. Defibrotide increases tissue plasminogen activator (t-PA) and decreases plasminogen activator inhibitor-1 activity. This increases the activity of plasmin, prevents blood clot formation and dissolves blood clots.
See also: Defibrotide Sodium (annotation moved to).

---

Drug Indication
Indicated for the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
FDA Label

---

Mechanism of Action
The drug appears to prevent the formation of blood clots and to help dissolve blood clots by increasing levels of prostaglandin I2, E2, and prostacyclin, altering platelet activity, increasing tissue plasminogen activator function, and decreasing activity of tissue plasminogen activator inhibitor. Prostaglandin I2 relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other. Prostaglandin E2 at certain concentrations also inhibits platelet aggregation. Moreover, the drug provides additional beneficial anti-inflammatory and antiischemic activities as recent sudies have shown. It is yet unclear, if the latter effects can be utilized clinically (e.g., treatment of ischemic stroke).

C20H21N4O6P

444.378

444.12

C, 54.06; H, 4.76; N, 12.61; O, 21.60; P, 6.97

1118915-78-8

1402907-09-8 (disodium);1118915-79-9 (monosodium);1118915-78-8 (free acid);83712-60-1(sodium);

135565962

Typically exists as solid at room temperature

1.987

152.41

4

7

5

31

773

0

CC(C)C1=CC(=C(C=C1OP(=O)(O)O)O)C2=NN=C(N2C3=CC=C4C(=C3)C=CN4C)O

JNWFIPVDEINBAI-UHFFFAOYSA-N

InChI=1S/C20H21N4O6P/c1-11(2)14-9-15(17(25)10-18(14)30-31(27,28)29)19-21-22-20(26)24(19)13-4-5-16-12(8-13)6-7-23(16)3/h4-11,25H,1-3H3,(H,22,26)(H2,27,28,29)

5-hydroxy-2-isopropyl-4-(4-(1-methyl-1H-indol-5-yl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)phenyl dihydrogen phosphate

STA-1474; ganetespib-prodrug; STA 1474; STA-9090 prodrug; STA1474; STA9090 prodrug

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。

---

注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。

View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

---

口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。

View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

---

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。